Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591773 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
A Phase 3 study of Hypertension, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
- 20
- Study locations
NCT00591773: Completed Phase 3 study of Hypertension, sponsored by Takeda.
NCT00591773 is a Phase 3 study of Hypertension that has completed, run by Takeda. The registered enrollment target is 551 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00591773, a Phase 3 study of Hypertension, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.
Primary Outcome
The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Conditions Studied
Interventions
- DRUG Chlorthalidone
- DRUG Azilsartan medoxomil and chlorthalidone
Study Locations (20)
California
- - Buena Park
- - Huntington Beach
- - Long Beach
- - Mission Viejo
- - Roseville
- - Sacramento
- - Westlake Village
Florida
- - Coral Gables
- - DeLand
- - Fort Lauderdale
- - Hollywood
- - Miami
North Carolina
- - Charlotte
- - Huntersville
- - Shelby
Alabama
- - Huntsville
- - Montgomery
Michigan
- - Bingham Farms
- - Troy
Maine
- - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
What the finished NCT00591773 record still lists
NCT00591773 is an interventional study that assigns participants to a tested intervention. The registered 551 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Chlorthalidone is the first listed.
NCT00591773 names 20 study sites across 6 states, led by California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00591773 about?
NCT00591773 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension". The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.
What is the current status of trial NCT00591773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2007-09. Estimated completion is 2009-03.
What conditions does trial NCT00591773 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00591773?
The interventions under investigation include: Chlorthalidone (DRUG), Azilsartan medoxomil and chlorthalidone (DRUG).
Who is sponsoring clinical trial NCT00591773?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00591773 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Maine, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00591773's enrollment target sits among peer trials
551 105th of 470 higher than 366 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia